Vol 31, No 1 (2024)
Experts' Viewpoint
Published online: 2023-12-29

open access

Page views 998
Article views/downloads 540
Get Citation

Connect on Social Media

Connect on Social Media

Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2023 update

Claudio Borghi1, Justyna Domienik-Karłowicz2, Andrzej Tykarski3, Krzysztof J. Filipiak45, Milosz J. Jaguszewski6, Krzysztof Narkiewicz7, Marcin Barylski8, Artur Mamcarz9, Jacek Wolf7, Giuseppe Mancia10
Pubmed: 38155566
Cardiol J 2024;31(1):1-14.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Borghi C, Tykarski A, Widecka K, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. Cardiol J. 2018; 25(5): 545–563.
  2. Borghi C, Domienik-Karłowicz J, Tykarski A, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update. Cardiol J. 2021; 28(1): 1–14.
  3. Bannasch D, Safra N, Young A, et al. Mutations in the SLC2A9 gene cause hyperuricosuria and hyperuricemia in the dog. PLoS Genet. 2008; 4(11): e1000246.
  4. Bobulescu IA, Moe OW. Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis. 2012; 19(6): 358–371.
  5. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011; 63(10): 3136–3141.
  6. Chen-Xu M, Yokose C, Rai SK, et al. Contemporary prevalence of gout and hyperuricemia in the united states and decadal trends: the national health and nutrition examination survey, 2007-2016. Arthritis Rheumatol. 2019; 71(6): 991–999.
  7. Centola M, Maloberti A, Castini D, et al. Impact of admission serum acid uric levels on in-hospital outcomes in patients with acute coronary syndrome. Eur J Intern Med. 2020; 82: 62–67.
  8. Maloberti A, Bossi I, Tassistro E, et al. Uric acid in chronic coronary syndromes: Relationship with coronary artery disease severity and left ventricular diastolic parameter. Nutr Metab Cardiovasc Dis. 2021; 31(5): 1501–1508.
  9. Maloberti A, Qualliu E, Occhi L, et al. Hyperuricemia prevalence in healthy subjects and its relationship with cardiovascular target organ damage. Nutr Metab Cardiovasc Dis. 2021; 31(1): 178–185.
  10. Piao W, Zhao L, Yang Y, et al. The prevalence of hyperuricemia and its correlates among adults in China: results from CNHS 2015-2017. Nutrients. 2022; 14(19).
  11. Kumar AUA, Browne LD, Li X, et al. Temporal trends in hyperuricaemia in the Irish health system from 2006-2014: A cohort study. PLoS One. 2018; 13(5): e0198197.
  12. Tsai CW, Lin SY, Kuo CC, et al. Serum uric acid and progression of kidney disease: a longitudinal analysis and mini-review. PLoS One. 2017; 12(1): e0170393.
  13. Williams B, Mancia G, Spiering W, et al. [2018 ESC/ESH Guidelines for the management of arterial hypertension]. Kardiol Pol. 2019; 77(2): 71–159.
  14. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA): Erratum. J Hypertens. 2024; 41(12): 1874–2071.
  15. Bombelli M, Ronchi I, Volpe M, et al. Prognostic value of serum uric acid: new-onset in and out-of-office hypertension and long-term mortality. J Hypertens. 2014; 32(6): 1237–1244.
  16. Virdis A, Masi S, Casiglia E, et al. Identification of the uric acid thresholds predicting an increased total and cardiovascular mortality over 20 years. Hypertension. 2020; 75(2): 302–308.
  17. Muiesan ML, Salvetti M, Virdis A, et al. Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study. J Hypertens. 2021; 39(1): 62–69.
  18. Muiesan ML, Agabiti Rosei C, Paini A, et al. Serum uric acid and left ventricular mass index independently predict cardiovascular mortality: The uric acid right for heart health (URRAH) project. Eur J Intern Med. 2023; 114: 58–65.
  19. Masulli M, D'Elia L, Angeli F, et al. Serum uric acid levels threshold for mortality in diabetic individuals: The URic acid Right for heArt Health (URRAH) project. Nutr Metab Cardiovasc Dis. 2022; 32(5): 1245–1252.
  20. Ungar A, Rivasi G, Di Bari M, et al. The association of uric acid with mortality modifies at old age: data from the uric acid right for heart health (URRAH) study. J Hypertens. 2022; 40(4): 704–711.
  21. Mengozzi A, Pugliese NR, Desideri G, et al. Serum uric acid predicts all-cause and cardiovascular mortality independently of hypertriglyceridemia in cardiometabolic patients without established CV disease: a sub-analysis of the URic acid Right for heArt Health (URRAH) study. Metabolites. 2023; 13(2).
  22. Casiglia E, Tikhonoff V, Virdis A, et al. Serum uric acid and fatal myocardial infarction: detection of prognostic cut-off values: The URRAH (Uric Acid Right for Heart Health) study. J Hypertens. 2020; 38(3): 412–419.
  23. Tikhonoff V, Casiglia E, Spinella P, et al. Identification of a plausible serum uric acid cut-off value as prognostic marker of stroke: the Uric Acid Right for Heart Health (URRAH) study. J Hum Hypertens. 2022; 36(11): 976–982.
  24. Muszyński P, Dąbrowski EJ, Pasławska M, et al. Hyperuricemia as a risk factor in hypertension among patients with very high cardiovascular risk. Healthcare (Basel). 2023; 11(17).
  25. Saito Y, Tanaka A, Node K, et al. Uric acid and cardiovascular disease: a clinical review. J Cardiol. 2021; 78(1): 51–57.
  26. Borghi C, Agabiti-Rosei E, Johnson RJ, et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med. 2020; 80: 1–11.
  27. Moshkovits Y, Tiosano S, Kaplan A, et al. Serum uric acid significantly improves the accuracy of cardiovascular risk score models. Eur J Prev Cardiol. 2023; 30(7): 524–532.
  28. Obrycki Ł, Feber J, Brzezińska G, et al. Evolution of isolated systolic hypertension with normal central blood pressure in adolescents-prospective study. Pediatr Nephrol. 2021; 36(2): 361–371.
  29. McEvoy RD, Antic NA, Heeley E, et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med. 2016; 375(10): 919–931.
  30. Kanbay A, Inonu H, Solak Y, et al. Uric acid as a potential mediator of cardiovascular morbidity in obstructive sleep apnea syndrome. Eur J Intern Med. 2014; 25(5): 471–476.
  31. Chen Q, Lin G, Chen L, et al. Does continuous positive airway pressure therapy in patients with obstructive sleep apnea improves uric acid? A meta-analysis. Oxid Med Cell Longev. 2019; 2019: 4584936.
  32. Wang A, Tian X, Wu S, et al. Metabolic factors mediate the association between serum uric acid to serum creatinine ratio and cardiovascular disease. J Am Heart Assoc. 2021; 10(23): e023054.
  33. Maloberti A, Biolcati M, Ruzzenenti G, et al. The role of uric acid in acute and chronic coronary syndromes. J Clin Med. 2021; 10(20).
  34. Mackenzie IS, Ford I, Walker A, et al. Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study. BMJ Open. 2016; 6(9): e013774.
  35. Mackenzie I, Hawkey C, Ford I, et al. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022; 400(10359): 1195–1205.
  36. Akashi N, Kuwabara M, Matoba T, et al. Hyperuricemia predicts increased cardiovascular events in patients with chronic coronary syndrome after percutaneous coronary intervention: A nationwide cohort study from Japan. Front Cardiovasc Med. 2022; 9: 1062894.
  37. Okura T, Higaki J, Kurata M, et al. Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis: subanalysis of the Japanese Coronary Artery Disease (JCAD) Study. Circ J. 2009; 73(5): 885–891.
  38. Grayson PC, Kim SY, LaValley M, et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011; 63(1): 102–110.
  39. Krishnan E, Kwoh CK, Schumacher HR, et al. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension. 2007; 49(2): 298–303.
  40. Perlstein TS, Gumieniak O, Williams GH, et al. Uric acid and the development of hypertension: the normative aging study. Hypertension. 2006; 48(6): 1031–1036.
  41. Forman JP, Choi H, Curhan GC. Uric acid and insulin sensitivity and risk of incident hypertension. Arch Intern Med. 2009; 169(2): 155–162.
  42. Mellen PB, Bleyer AJ, Erlinger TP, et al. Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension. 2006; 48(6): 1037–1042.
  43. Zhang W, Sun K, Yang Y, et al. Plasma uric acid and hypertension in a Chinese community: prospective study and metaanalysis. Clin Chem. 2009; 55(11): 2026–2034.
  44. Shankar A, Klein R, Klein BEK, et al. The association between serum uric acid level and long-term incidence of hypertension: Population-based cohort study. J Hum Hypertens. 2006; 20(12): 937–945.
  45. Sundström J, Sullivan L, D'Agostino RB, et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension. 2005; 45(1): 28–33.
  46. White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018; 378(13): 1200–1210.
  47. Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017; 15(1): 123.
  48. Mackenzie I, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020; 396(10264): 1745–1757.
  49. Keenan RT, Pillinger MH. Febuxostat: A new agent for lowering serum urate. Drugs Today. 2009; 45(4): 247.
  50. Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353(23): 2450–2461.
  51. Ghossan R, Aitisha O, Fayad F, et al. POS0520 cardiovascular safety of febuxostat in patients with gout or hyperuricemia: a systematic review of randomized controlled trials. Scientific Abstracts. 2023; 82(Suppl 1): 523.
  52. Borghi C, Rosei EA, Bardin T, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015; 33(9): 1729–1741.
  53. Puig JG, Martínez MA. Hyperuricemia, gout and the metabolic syndrome. Curr Opin Rheumatol. 2008; 20(2): 187–191.
  54. Yu KH, Kuo CF, Luo SF, et al. Risk of end-stage renal disease associated with gout: a nationwide population study. Arthritis Res Ther. 2012; 14(2): R83.
  55. Abbott RD, Brand FN, Kannel WB, et al. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol. 1988; 41(3): 237–242.
  56. De Vera MA, Rahman MM, Bhole V, et al. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann Rheum Dis. 2010; 69(6): 1162–1164.
  57. Matsumura K, Arima H, Tominaga M, et al. Effect of losartan on serum uric acid in hypertension treated with a diuretic: the COMFORT study. Clin Exp Hypertens. 2015; 37(3): 192–196.
  58. Jacob RA, Spinozzi GM, Simon VA, et al. Consumption of cherries lowers plasma urate in healthy women. J Nutr. 2003; 133(6): 1826–1829.
  59. Ralston SH, Capell HA, Sturrock RD. Alcohol and response to treatment of gout. Br Med J (Clin Res Ed). 1988; 296(6637): 1641–1642.
  60. Richette P, Poitou C, Manivet P, et al. Weight loss, xanthine oxidase, and serum urate levels: a prospective longitudinal study of obese patients. Arthritis Care Res (Hoboken). 2016; 68(7): 1036–1042.
  61. Chen JH, Wen CP, Wu SB, et al. Attenuating the mortality risk of high serum uric acid: the role of physical activity underused. Ann Rheum Dis. 2015; 74(11): 2034–2042.
  62. Schlesinger N. Dietary factors and hyperuricaemia. Curr Pharm Des. 2005; 11(32): 4133–4138.
  63. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017; 76(1): 29–42.
  64. Kochanowska A, Rusztyn P, Szczerkowska K, et al. Sodium-Glucose cotransporter 2 inhibitors to decrease the uric acid concentration-a novel mechanism of action. J Cardiovasc Dev Dis. 2023; 10(7): 268.
  65. Deeks ED. Lesinurad: a review in hyperuricaemia of gout. Drugs Aging. 2017; 34(5): 401–410.
  66. Pérez-Ruiz F, Jansen T, Tausche AK, et al. Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout. Drugs Context. 2019; 8: 212581.
  67. Saag KG, Fitz-Patrick D, Kopicko J, et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a us-based study). Arthritis Rheumatol. 2017; 69(1): 203–212.
  68. Dalbeth N, Jones G, Terkeltaub R, et al. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. Arthritis Res Ther. 2019; 21(1): 8.